Prone versus Supine FDG PET/CT in the Staging of Breast Cancer
Lara Nassar,
Mutaz Kassas,
Alain S. Abi-Ghanem,
Malak El-Jebai,
Safaa Al-Zakleet,
Amro S. Baassiri,
Rami Abou Naccoul,
Andrew Barakat,
Arafat Tfayli,
Hazem Assi,
Ghina Berjawi,
Enrique Estrada-Lobato,
Francesco Giammarile,
Sobhan Vinjamuri,
Mohamad Haidar
Affiliations
Lara Nassar
Department of Diagnostic Radiology, American University of Beirut Medical Center, Beirut 1107-2020, Lebanon
Mutaz Kassas
Department of Diagnostic Radiology, American University of Beirut Medical Center, Beirut 1107-2020, Lebanon
Alain S. Abi-Ghanem
Department of Diagnostic Radiology, American University of Beirut Medical Center, Beirut 1107-2020, Lebanon
Malak El-Jebai
Department of Diagnostic Radiology, American University of Beirut Medical Center, Beirut 1107-2020, Lebanon
Safaa Al-Zakleet
Department of Diagnostic Radiology, American University of Beirut Medical Center, Beirut 1107-2020, Lebanon
Amro S. Baassiri
Yale Cancer Center, Yale School of Medicine, New Haven, CT 06520-8028, USA
Rami Abou Naccoul
Department of Diagnostic Radiology, American University of Beirut Medical Center, Beirut 1107-2020, Lebanon
Andrew Barakat
Department of Diagnostic Radiology, American University of Beirut Medical Center, Beirut 1107-2020, Lebanon
Arafat Tfayli
Department of Internal Medicine, Division of Hematology and Oncology, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Beirut 1107-2020, Lebanon
Hazem Assi
Department of Internal Medicine, Division of Hematology and Oncology, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Beirut 1107-2020, Lebanon
Ghina Berjawi
Department of Diagnostic Radiology, American University of Beirut Medical Center, Beirut 1107-2020, Lebanon
Enrique Estrada-Lobato
Nuclear Medicine and Diagnostic Imaging Section, Division of Human Health, International Atomic Energy Agency, Vienna 1400, Austria
Francesco Giammarile
Nuclear Medicine and Diagnostic Imaging Section, Division of Human Health, International Atomic Energy Agency, Vienna 1400, Austria
Sobhan Vinjamuri
Nuclear Medicine, Royal Liverpool and Broadgreen University Hospital, Liverpool L7-8YE, UK
Mohamad Haidar
Department of Diagnostic Radiology, American University of Beirut Medical Center, Beirut 1107-2020, Lebanon
Supine [18F]Fluorodeoxyglucose (FDG) positron emission technology/computed tomography (PET/CT) is a commonly used modality for the initial staging of breast cancer, and several previous studies have shown superior sensitivity and specificity of prone FDG PET/CT in comparison to its supine counterpart. This retrospective study included 25 females with breast cancer referred for staging. They underwent supine FDG PET/CT followed by prone FDG PET/CT. The outcomes were: number of primary breast lesions, anatomical site of FDG-avid lymph nodes (LNs), and number and type of bone lesions, with SUVmax of all corresponding parameters. Performance was superior in prone acquisition compared to supine acquisition, with the respective results: 29 vs. 22 breast tumor lesions detected, 62 vs. 27 FDG-avid axillary LNs detected, sensitivity of 68% vs. 57%, specificity of 64% vs. 53%. The detection rate of axillary LNs in the prone position was significantly higher (p = 0.001). SUVmax for breast tumor lesions (p = 0.000) and number of detected axillary LNs (p = 0.002) were significantly higher in prone acquisition. Five patients were upstaged after experts read the prone acquisition. Prone FDG PET/CT acquisition is a promising technique in detecting primary breast lesions and metastatic LNs possibly missed in supine acquisition, which may lead to change in patient staging and management.